FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000838928> ?p ?o ?g. }

• W2000838928 endingPage "195" @default.
• W2000838928 startingPage "191" @default.
• W2000838928 abstract "Objectives.The aims of this study were (1) to assess a treatment policy for patients with low-risk endometrioid endometrial carcinoma where adjuvant treatment decisions have been based on ploidy status of the tumor, and (2) to screen diploid, low-risk tumors for additional features of prognostic significance. Methods.Between 01/1992 and 08/1996, 406 patients were referred to the B.C. Cancer Agency–Vancouver Clinic with typical endometrial adenocarcinomas limited to <50% myometrial invasion and no vascular space invasion or grade 3 disease on pathology review (“low-risk stage I endometrial carcinoma”). Patients were prospectively assigned to treatment groups based on tumor ploidy. Those patients with aneuploid tumors (n= 91) were treated with adjuvant vaginal vault radiotherapy while those with diploid tumors (n= 315) were followed and treated only at relapse. The hysterectomy specimens from all 14 patients in the untreated, diploid group who relapsed, as well as 28 stage- and grade-matched diploid controls who did not fail, were analyzed by immunohistochemical staining for estrogen receptor (ER), Bcl-2, and p53 proteins. Results.There were no significant differences in the stage (Ia vs Ib) and grade (G1 vs G2) distribution for the diploid and aneuploid groups. Overall median age was 64 years (range 27–90 years) and was also not significantly different for the two groups. The median follow-up for the entire cohort is 45 months (range 1–76 months). There have been 14 failures in the diploid group and 4 failures in the aneuploid group with actuarial 5-year disease-free survival rates of 95.0 and 95.2%, respectively (P= NS). Eight of the failures in the diploid group occurred at the vaginal vault and were all subsequently salvaged with radiotherapy. All but 1 of the failures in the aneuploid group were considered incurable. Of the 14 diploid tumors from patients who failed, 7 stained positively for p53, compared to 4 of 28 diploid controls (P= 0.02). No significant differences were seen in the diploid tumors that recurred, compared to controls, with respect to Bcl-2 or ER expression. Conclusions.Patients with diploid, low-risk stage I endometrial cancers have excellent prospects for relapse-free and overall survival. Patients with aneuploid tumors treated with adjuvant radiotherapy have the same risk of relapse as untreated patients with diploid tumors; however, their ultimate survival may be lower as a smaller proportion of aneuploid failures are salvageable. While p53 expression in diploid tumors is associated with increased risk of relapse, Bcl-2 and ER are not useful prognostic indicators in this setting." @default.
• W2000838928 created "2016-06-24" @default.
• W2000838928 creator A5021930138 @default.
• W2000838928 creator A5028168555 @default.
• W2000838928 creator A5045148327 @default.
• W2000838928 creator A5058502297 @default.
• W2000838928 creator A5060626037 @default.
• W2000838928 creator A5066786840 @default.
• W2000838928 creator A5073854833 @default.
• W2000838928 date "1999-05-01" @default.
• W2000838928 modified "2023-09-27" @default.
• W2000838928 title "Low-Risk Endometrial Carcinoma: Assessment of a Treatment Policy Based on Tumor Ploidy and Identification of Additional Prognostic Indicators" @default.
• W2000838928 cites W1972450145 @default.
• W2000838928 cites W1978184587 @default.
• W2000838928 cites W1986419741 @default.
• W2000838928 cites W1992374093 @default.
• W2000838928 cites W1999290768 @default.
• W2000838928 cites W2006638972 @default.
• W2000838928 cites W2007836981 @default.
• W2000838928 cites W2009867490 @default.
• W2000838928 cites W2010066662 @default.
• W2000838928 cites W2013959373 @default.
• W2000838928 cites W2015634396 @default.
• W2000838928 cites W2016558284 @default.
• W2000838928 cites W2018708063 @default.
• W2000838928 cites W2035269440 @default.
• W2000838928 cites W2041340510 @default.
• W2000838928 cites W2043001404 @default.
• W2000838928 cites W2045350668 @default.
• W2000838928 cites W2053670125 @default.
• W2000838928 cites W2061231123 @default.
• W2000838928 cites W2077680688 @default.
• W2000838928 cites W2090181843 @default.
• W2000838928 cites W2090970424 @default.
• W2000838928 cites W2094161649 @default.
• W2000838928 cites W2170178839 @default.
• W2000838928 cites W2170234323 @default.
• W2000838928 cites W2313154424 @default.
• W2000838928 cites W2325681859 @default.
• W2000838928 cites W4229610456 @default.
• W2000838928 doi "https://doi.org/10.1006/gyno.1999.5365" @default.
• W2000838928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10329033" @default.
• W2000838928 hasPublicationYear "1999" @default.
• W2000838928 type Work @default.
• W2000838928 sameAs 2000838928 @default.
• W2000838928 citedByCount "25" @default.
• W2000838928 countsByYear W20008389282012 @default.
• W2000838928 countsByYear W20008389282013 @default.
• W2000838928 countsByYear W20008389282014 @default.
• W2000838928 countsByYear W20008389282015 @default.
• W2000838928 countsByYear W20008389282017 @default.
• W2000838928 countsByYear W20008389282020 @default.
• W2000838928 countsByYear W20008389282022 @default.
• W2000838928 crossrefType "journal-article" @default.
• W2000838928 hasAuthorship W2000838928A5021930138 @default.
• W2000838928 hasAuthorship W2000838928A5028168555 @default.
• W2000838928 hasAuthorship W2000838928A5045148327 @default.
• W2000838928 hasAuthorship W2000838928A5058502297 @default.
• W2000838928 hasAuthorship W2000838928A5060626037 @default.
• W2000838928 hasAuthorship W2000838928A5066786840 @default.
• W2000838928 hasAuthorship W2000838928A5073854833 @default.
• W2000838928 hasConcept C121608353 @default.
• W2000838928 hasConcept C126322002 @default.
• W2000838928 hasConcept C142724271 @default.
• W2000838928 hasConcept C143998085 @default.
• W2000838928 hasConcept C146357865 @default.
• W2000838928 hasConcept C151730666 @default.
• W2000838928 hasConcept C2777088508 @default.
• W2000838928 hasConcept C2777546739 @default.
• W2000838928 hasConcept C2777982462 @default.
• W2000838928 hasConcept C2779494336 @default.
• W2000838928 hasConcept C29456083 @default.
• W2000838928 hasConcept C71924100 @default.
• W2000838928 hasConcept C86803240 @default.
• W2000838928 hasConceptScore W2000838928C121608353 @default.
• W2000838928 hasConceptScore W2000838928C126322002 @default.
• W2000838928 hasConceptScore W2000838928C142724271 @default.
• W2000838928 hasConceptScore W2000838928C143998085 @default.
• W2000838928 hasConceptScore W2000838928C146357865 @default.
• W2000838928 hasConceptScore W2000838928C151730666 @default.
• W2000838928 hasConceptScore W2000838928C2777088508 @default.
• W2000838928 hasConceptScore W2000838928C2777546739 @default.
• W2000838928 hasConceptScore W2000838928C2777982462 @default.
• W2000838928 hasConceptScore W2000838928C2779494336 @default.
• W2000838928 hasConceptScore W2000838928C29456083 @default.
• W2000838928 hasConceptScore W2000838928C71924100 @default.
• W2000838928 hasConceptScore W2000838928C86803240 @default.
• W2000838928 hasIssue "2" @default.
• W2000838928 hasLocation W20008389281 @default.
• W2000838928 hasLocation W20008389282 @default.
• W2000838928 hasOpenAccess W2000838928 @default.
• W2000838928 hasPrimaryLocation W20008389281 @default.
• W2000838928 hasRelatedWork W1758517966 @default.
• W2000838928 hasRelatedWork W2491745425 @default.
• W2000838928 hasRelatedWork W2992256246 @default.
• W2000838928 hasRelatedWork W3045002936 @default.
• W2000838928 hasRelatedWork W3102087269 @default.
• W2000838928 hasRelatedWork W3106451637 @default.

• next